Thursday, May 9, 2013 - Thursday, May 9, 2013
8:00 a.m. - 10:00 a.m.
Add to Calendar
Wednesday, May 8, 2013 12:00 p.m.
Where BIOCOM Boardroom
4510 Executive Drive, Plaza 7
San Diego, California 92121
Virtual Drug Development in Southern California: A Pre-Clinical Focus
Being an early stage virtual company is no easy task. Managing resources and timelines while minimizing costs are the new normal for successful virtual companies. This two hour event and panel discussion hosted by Explora Biolabs and MPI Research will explore successful preclinical drug development in a virtual setting. Explora BioLabs will discuss selecting a drug candidate using early biology/efficacy models as well as best practices for screening and partnering with a CRO to streamline your candidate selection in a resource constrained environment. Building on that discussion, MPI Research will describe how to advance a compound from early GLP tox and safety testing into phase 1 while utilizing successful partnerships.
Joining the presenters for a follow-on panel discussion will be:
David Johnson, Director of DMPK, MicroConstants, Inc.
Richard Lin, CEO, Explora Biolabs
Greg Ruppert, Sr. Study Director and Director of Sales, MPI Research
Jennifer Spinella, Vice President, Regulatory Affairs & Quality Assurance, Rare Disease Therapeutics